Nasdaq
$1.91▼ 4.50%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.2MShares out 1.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 10.15After-hours26.10.16 06:258-KKey event#●●●
Ernexa Therapeutics Inc.
Ernexa Therapeutics released an investor presentation on October 15, 2026. The presentation materials are available for review on the company's official website under the Investor Relations section.…more
$1.91-4.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 05:133Ownership
Ernexa Therapeutics Inc.
Robert J. Spiegel, a director of Ernexa Therapeutics Inc., filed a Form 3 to disclose his initial beneficial ownership of securities as of September 14, 2026. This filing serves as an official notification of the director's equity holdings.…more
$1.91-4.50%vs prev closeView filingShare - 9.16After-hours26.09.17 06:308-KKey event
Ernexa Therapeutics Inc.
Ernexa Therapeutics released its corporate fact sheet and investor presentation on September 16, 2026. These materials are available on the company's investor relations website, which will serve as a primary channel for distributing important company information.…more
$1.91-4.50%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:53#●●●#●●●
Ernexa Therapeutics Updates on ERNA-101 Clinical Path and Platform Strategy…more
Ernexa Therapeutics released an investor segment detailing its regulatory progress with the FDA and the scientific foundation for its ERNA-101 cell therapy. The company is currently transitioning toward first-in-human clinical trials, though no specific timeline for clinical initiation was confirmed.…more
$1.91-4.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.12After-hours26.10.13 05:05
●●●●●●●● ●●●●● ●●●●●●
Ernexa Therapeutics executives will participate in a virtual investor conference to provide a corporate overview and update on the clinical development of its lead candidate, ERNA-101. The event will include a moderated discussion and a live Q&A session for investors.…more
$1.91-4.50%vs prev close - 10.6Pre-market26.10.06 21:55
●●●●●●●● ●●●●● ●●●●●●
Ernexa Therapeutics will present preclinical data for its ovarian cancer candidate ERNA-101 at an upcoming cancer therapeutics meeting. While the candidate showed tumor regression in animal models, it remains in the preclinical stage pending human clinical trials.…more
$1.91-4.50%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report